Biora Therapeutics is a biotechnology company developing oral biotherapeutics. Co.'s therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP Targeted Oral Delivery Platform and BIOJET Systemic Oral Delivery Platform. Co.'s Targeted Therapeutics program includes BT-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis. Co.'s Systemic Therapeutics program includes BT-002, a combination product of a variant of adalimumab and the BIOJET device for the treatment of inflammatory conditions; as well as BT-200, a combination product of a GLP-1 receptor agonist and the BIOJET device for the treatment of type 2 diabetes. The BIOR average annual return since 2020 is shown above.
The Average Annual Return on the BIOR average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BIOR average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BIOR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|